teicoplanin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
glycopeptide antibacterials (Actinoplanes strains) 2998 61036-62-2

Description:

MoleculeDescription

Synonyms:

  • teicoplanin
  • Antibiotic 8327A
  • Antibiotic MDL 507
  • targocid
  • targosid
  • teichomycin
Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.40 g P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 221.99 32.99 84 4196 33752 63450990
Thrombocytopenia 87.41 32.99 76 4204 151081 63333661
Acinetobacter infection 84.82 32.99 20 4260 1563 63483179
Stenotrophomonas infection 74.94 32.99 19 4261 2008 63482734
Pyrexia 72.32 32.99 120 4160 470358 63014384
Septic shock 65.71 32.99 46 4234 66583 63418159
Multiple organ dysfunction syndrome 62.62 32.99 42 4238 56710 63428032
Anaphylactic reaction 61.40 32.99 44 4236 66056 63418686
Drug resistance 54.73 32.99 28 4252 22905 63461837
Enterococcal infection 53.22 32.99 20 4260 7828 63476914
Neutropenia 52.97 32.99 62 4218 174943 63309799
Rash maculo-papular 51.31 32.99 30 4250 31866 63452876
Mental status changes postoperative 49.56 32.99 9 4271 191 63484551
Confusion postoperative 47.70 32.99 9 4271 237 63484505
Haemodynamic instability 46.70 32.99 19 4261 9171 63475571
Acute generalised exanthematous pustulosis 46.51 32.99 20 4260 11079 63473663
Cross sensitivity reaction 45.55 32.99 13 4267 2149 63482593
Morganella infection 44.04 32.99 10 4270 661 63484081
Eosinophilia 43.60 32.99 24 4256 22732 63462010
Pathogen resistance 42.28 32.99 16 4264 6382 63478360
Haemostasis 41.33 32.99 8 4272 242 63484500
Klebsiella infection 41.11 32.99 17 4263 8549 63476193
Bronchopulmonary aspergillosis 40.98 32.99 17 4263 8618 63476124
Pancytopenia 40.97 32.99 41 4239 96892 63387850
Febrile neutropenia 40.96 32.99 45 4235 118404 63366338
Renal impairment 38.50 32.99 38 4242 88317 63396425
Sepsis 36.26 32.99 48 4232 153075 63331667

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 147.17 24.23 82 5622 32930 34918297
Pyrexia 116.85 24.23 200 5504 332813 34618414
Cross sensitivity reaction 88.04 24.23 24 5680 1373 34949854
Multiple organ dysfunction syndrome 79.58 24.23 79 5625 76487 34874740
Venoocclusive disease 71.02 24.23 24 5680 2843 34948384
Foetal cardiac arrest 65.91 24.23 10 5694 21 34951206
Neutropenia 65.17 24.23 102 5602 156676 34794551
Anal inflammation 62.18 24.23 18 5686 1282 34949945
Thrombocytopenia 61.28 24.23 99 5605 156148 34795079
Rash maculo-papular 59.73 24.23 44 5660 28407 34922820
SARS-CoV-2 test negative 52.70 24.23 15 5689 1005 34950222
Systemic mycosis 50.40 24.23 16 5688 1557 34949670
Eosinophilia 47.19 24.23 37 5667 26185 34925042
Hyphaema 46.08 24.23 12 5692 575 34950652
Fatigue 45.90 24.23 4 5700 370649 34580578
Systemic candida 43.62 24.23 18 5686 3708 34947519
Septic shock 40.37 24.23 54 5650 71780 34879447
Febrile neutropenia 39.67 24.23 76 5628 136773 34814454
Accident 38.37 24.23 18 5686 5029 34946198
Cytomegalovirus infection 36.83 24.23 32 5672 26103 34925124
Stevens-Johnson syndrome 35.05 24.23 27 5677 18612 34932615
Geotrichum infection 33.35 24.23 9 5695 495 34950732
Drug resistance 33.06 24.23 30 5674 25897 34925330
Acute kidney injury 32.32 24.23 116 5588 304872 34646355
Thrombotic microangiopathy 30.66 24.23 20 5684 10610 34940617
Haemophagocytic lymphohistiocytosis 29.34 24.23 21 5683 12952 34938275
Renal impairment 29.23 24.23 54 5650 94459 34856768
Coagulation time prolonged 28.74 24.23 10 5694 1292 34949935
Cellulitis 28.50 24.23 39 5665 52912 34898315
Body temperature increased 28.03 24.23 23 5681 17345 34933882
Brain abscess 26.42 24.23 12 5692 3113 34948114
COVID-19 pneumonia 26.40 24.23 22 5682 16945 34934282
C-reactive protein increased 26.37 24.23 38 5666 54060 34897167
Death 25.37 24.23 17 5687 398032 34553195
Mast cell degranulation present 25.21 24.23 5 5699 68 34951159
Respiratory gas exchange disorder 24.65 24.23 7 5697 465 34950762
Flavobacterium infection 24.40 24.23 5 5699 81 34951146

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 339.58 22.95 164 9830 64080 79670314
Pyrexia 185.15 22.95 315 9679 678394 79056000
Thrombocytopenia 146.58 22.95 173 9821 265086 79469308
Multiple organ dysfunction syndrome 132.24 22.95 114 9880 120132 79614262
Cross sensitivity reaction 125.45 22.95 37 9957 3675 79730719
Neutropenia 119.78 22.95 163 9831 287547 79446847
Rash maculo-papular 107.46 22.95 74 9920 56004 79678390
Acinetobacter infection 104.09 22.95 30 9964 2747 79731647
Septic shock 101.02 22.95 99 9895 122702 79611692
Eosinophilia 89.62 22.95 61 9933 45284 79689110
Anaphylactic reaction 81.23 22.95 74 9920 83669 79650725
Stenotrophomonas infection 78.69 22.95 26 9968 3747 79730647
Febrile neutropenia 74.34 22.95 116 9878 230883 79503511
Drug resistance 72.24 22.95 52 9942 42161 79692233
Venoocclusive disease 69.99 22.95 25 9969 4548 79729846
Fatigue 65.39 22.95 18 9976 929709 78804685
Systemic mycosis 62.19 22.95 20 9974 2646 79731748
Enterococcal infection 62.15 22.95 33 9961 15627 79718767
Anal inflammation 60.58 22.95 17 9977 1413 79732981
Geotrichum infection 52.42 22.95 14 9980 967 79733427
Sepsis 51.61 22.95 108 9886 269320 79465074
Pancytopenia 51.56 22.95 82 9912 165663 79568731
Acute kidney injury 51.27 22.95 162 9832 519242 79215152
Renal impairment 50.37 22.95 79 9915 157704 79576690
SARS-CoV-2 test negative 47.79 22.95 14 9980 1357 79733037
Systemic candida 44.25 22.95 20 9974 6686 79727708
Hyphaema 44.07 22.95 12 9982 892 79733502
Stevens-Johnson syndrome 42.70 22.95 37 9957 39129 79695265
Toxic skin eruption 41.68 22.95 29 9965 22264 79712130
Fall 41.34 22.95 6 9988 487623 79246771
Dizziness 41.27 22.95 8 9986 526433 79207961
Fungaemia 41.15 22.95 17 9977 4574 79729820
Haemodynamic instability 40.67 22.95 26 9968 17356 79717038
C-reactive protein increased 40.33 22.95 64 9930 128963 79605431
Off label use 40.16 22.95 221 9773 906994 78827400
Haemophagocytic lymphohistiocytosis 39.88 22.95 28 9966 21809 79712585
Mental status changes postoperative 38.78 22.95 8 9986 177 79734217
Cytomegalovirus infection 38.06 22.95 36 9958 42608 79691786
Klebsiella infection 37.99 22.95 24 9970 15696 79718698
Confusion postoperative 37.32 22.95 8 9986 214 79734180
Acute generalised exanthematous pustulosis 35.95 22.95 24 9970 17230 79717164
Toxic epidermal necrolysis 34.85 22.95 35 9959 44546 79689848
Dyspnoea 34.57 22.95 34 9960 856991 78877403
Cholestasis 33.75 22.95 37 9957 52072 79682322
Weight decreased 33.51 22.95 3 9991 355195 79379199
Drug ineffective 33.28 22.95 240 9754 1080673 78653721
Morganella infection 32.75 22.95 10 9984 1117 79733277
Haemostasis 32.59 22.95 8 9986 394 79734000
Headache 32.53 22.95 21 9973 653751 79080643
Pathogen resistance 32.44 22.95 21 9973 14321 79720073
Accident 30.56 22.95 17 9977 8814 79725580
Thrombotic microangiopathy 30.34 22.95 23 9971 20146 79714248
Fungal infection 29.42 22.95 31 9963 41717 79692677
Staphylococcal infection 28.76 22.95 36 9958 58259 79676135
Cellulitis 28.58 22.95 50 9944 109010 79625384
Disseminated mucormycosis 27.67 22.95 8 9986 740 79733654
Mast cell degranulation present 26.53 22.95 5 9989 68 79734326
Hyperbilirubinaemia 26.39 22.95 23 9971 24495 79709899
Asthenia 26.03 22.95 16 9978 511673 79222721
Coagulation time prolonged 24.97 22.95 10 9984 2485 79731909
Flavobacterium infection 24.81 22.95 5 9989 98 79734296
Fusarium infection 24.25 22.95 9 9985 1823 79732571
Brain abscess 24.21 22.95 12 9982 4924 79729470
Bronchopulmonary aspergillosis 24.17 22.95 21 9973 22273 79712121
Platelet count decreased 24.17 22.95 66 9928 194598 79539796
Pain in extremity 23.82 22.95 8 9986 364530 79369864
Dermatitis bullous 23.11 22.95 17 9977 14228 79720166

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XA02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Staphylococcal infectious disease indication 56038003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4025272 VUID
N0000171799 NUI
D02142 KEGG_DRUG
4025272 VANDF
C0145106 UMLSCUI
CHEBI:29687 CHEBI
CHEMBL4297166 ChEMBL_ID
CHEMBL2367892 ChEMBL_ID
D017334 MESH_DESCRIPTOR_UI
DB06149 DRUGBANK_ID
10924 IUPHAR_LIGAND_ID
5155 INN_ID
4U3D3YY81M UNII
133065662 PUBCHEM_CID
196469 RXNORM
003765 NDDF
387529008 SNOMEDCT_US
96014005 SNOMEDCT_US

Pharmaceutical products:

None